Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

• Hauptverfasser: Qiongwen Zhang (VerfasserIn), Ping He (VerfasserIn), Tinglun Tian (VerfasserIn), Xi Yan (VerfasserIn), Juan Huang (VerfasserIn), Zhang Zhang (VerfasserIn), Hong Zheng (VerfasserIn), Xiaorong Zhong (VerfasserIn), Ting Luo (VerfasserIn)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Background: Pyrotinib, a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor, shows encouraging anticancer activity and acceptable tolerability in multiple phase II and phase III randomized clinical trials, but the real-world data of pyrotinib, especially the outcomes in HER2-positive metast...